1. Habermann ET, Sachs R, Stern RE, Hirsh DM, Anderson WJ. The
pathology and treatment of metastatic disease of the femur.
Clin Orthop Relat Res. 1982 ;( 169):70-82.
2. Mirels H. Metastatic disease in long bones. A proposed scoring
system for diagnosing impending pathologic fractures. Clin
Orthop Relat Res. 1989 ;( 249):256-264.
3. Bickels J, Dadia S, Lidar Z. Surgical management of metastatic
bone disease. J Bone Joint Surg Am. 2009; 91(6):1503-1516.
doi:10.2106/JBJS.H.00175.
4. Brauer CA, Coca-Perraillon M, Cutler DM, Rosen AB. Incidence
and mortality of hip fractures in the United States. JAMA.
2009; 302(14):1573-1579. doi:10.1001/jama.2009.1462.
5. Johnell O, Kanis JA. An estimate of the worldwide prevalence,
mortality and disability associated with hip fracture.
Osteoporos Int. 2004; 15(11):897-902. doi:10.1007/s00198-
004-1627-0.
6. Tay E. Hip fractures in the elderly: operative versus
nonoperative management. Singapore Med J. 2016;
57(4):178-181. doi:10.11622/smedj.2016071.
7. Khattak MJ, Ashraf U, Nawaz Z, Noordin S, Umer M. Surgical
management of metastatic lesions of proximal femur and the
hip. Ann Med Surg (Lond). 2018; 36:90-95.
doi:10.1016/j.amsu.2018.09.042.
8. Boateng B, Bartelstein M. Timing of systemic cancer therapy
relative to surgery to optimize wound healing: Do guidelines
exist? Presented at: Annual Biomedical Research Conference
for Minority Students. 2021; virtual meeting.
9. Mellor JD, Cassumbhoy M, Jefford M. Clinical guidance on the
perioperative use of targeted agents in solid tumor oncology.
Asia Pac J Clin Oncol. 2011; 7(2):106-113.
doi:10.1111/j.1743-7563.2011.01394.x.
10. Yang Y, Lu Y, Tan H, et al. The optimal time of starting
adjuvant chemotherapy after curative surgery in patients
with colorectal cancer. BMC Cancer. 2023; 23(1):422.
doi:10.1186/s12885-023-10863-w.
11. Imran H, Enders F, Krailo M, et al. Effect of time to resumption
of chemotherapy after definitive surgery on prognosis for
non-metastatic osteosarcoma. J Bone Joint Surg Am. 2009;
91(3):604-612. doi:10.2106/JBJS.H.00449.
12. Deptuła M, Zieliński J, Wardowska A, Pikuła M. Wound
healing complications in oncological patients: perspectives
for cellular therapy. Postepy Dermatol Alergol. 2019;
36(2):139-146. doi:10.5114/ada.2018.72585.
13. Keating GM. Bevacizumab: a review of its use in advanced
cancer. Drugs. 2014; 74(16):1891-1925.
doi:10.1007/s40265-014-0302-9.
14. Sharma K, Marcus JR. Bevacizumab and wound-healing
complications: mechanisms of action, clinical evidence, and
management recommendations for the plastic surgeon. Ann
Plast Surg. 2013; 71(4):434-440.
doi:10.1097/SAP.0b013e31824e5e57.
15. Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical
wound healing complications in metastatic colorectal cancer
patients treated with bevacizumab. J Surg Oncol. 2005;
91(3):173-180. doi:10.1002/jso.20301.
16. Erinjeri JP, Fong AJ, Kemeny NE, Brown KT, Getrajdman GI,
Solomon SB. Timing of administration of bevacizumab
chemotherapy affects wound healing after chest wall port
placement. Cancer. 2011; 117(6):1296-1301.
doi:10.1002/cncr.25573.
17. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and
pharmacokinetic study of recombinant human anti-vascular
endothelial growth factor in patients with advanced cancer. J
Clin Oncol. 2001; 19(3):843-850.
doi:10.1200/JCO.2001.19.3.843.
18. Gordon CR, Rojavin Y, Patel M, et al. A review on bevacizumab
and surgical wound healing: an important warning to all
surgeons. Ann Plast Surg. 2009; 62(6):707-709.
doi:10.1097/SAP.0b013e3181828141.
19. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab
plus irinotecan, fluorouracil, and leucovorin for metastatic
colorectal cancer. N Engl J Med. 2004; 350(23):2335-42.
doi:10.1056/NEJMoa032691.
20. Ellis LM, Curley SA, Grothey A. Surgical resection after
downsizing of colorectal liver metastasis in the era of
bevacizumab. J Clin Oncol. 2005; 23(22):4853-4855.
doi:10.1200/JCO.2005.23.754.
21. Utsumi H, Honma Y, Nagashima K, et al. Bevacizumab and
postoperative wound complications in patients with liver
metastases of colorectal cancer. Anticancer Res. 2015;
35(4):2255-2261.
22. Zhang H, Huang Z, Zou X, Liu T. Bevacizumab and woundhealing complications: a systematic review and meta-analysis
of randomized controlled trials. Oncotarget. 2016;
7(50):82473-82481. doi:10.18632/oncotarget.12666.
23. Mahfud M, Breitenstein S, El-Badry AM, et al. Impact of preoperative bevacizumab on complications after resection
of colorectal liver metastases: case-matched control study.
World J Surg. 2010; 34(1):92-100. doi:10.1007/s00268-009-
0251-8.
24. Clark AJ, Butowski NA, Chang SM, et al. Impact of
bevacizumab chemotherapy on craniotomy wound healing. J
Neurosurg. 2011; 114(6):1609-1616.
doi:10.3171/2010.10.JNS101042.
25. Drake DB, Oishi SN. Wound healing considerations in
chemotherapy and radiation therapy. Clin Plast Surg. 1995;
22(1):31-37.
26. Giakoustidis A, Morrison D, Neofytou K, Giakoustidis D,
Mudan S. Emergency open incarcerated hernia repair with a
biological mesh in a patient with colorectal liver metastasis
receiving chemotherapy and bevacizumab uncomplicated
wound healing. Case Rep Emerg Med. 2014:2014:848030.
doi:10.1155/2014/848030.
27. Hyldig N, Birke-Sorensen H, Kruse M, et al. Meta-analysis of
negative-pressure wound therapy for closed surgical
incisions. Br J Surg. 2016; 103(5):477-486.
doi:10.1002/bjs.10084.
28. Meynard P, Seguineau A, Laumonerie P, et al. Surgical
management of proximal femoral metastasis: fixation or hip
replacement? A 309 case series. Orthop Traumatol Surg Res.
2020; 106(6):1013-1023. doi:10.1016/j.otsr.2020.05.007.
)